Robert A Fletcher

8PUBLICATIONS
148CO-AUTHORS
Gene expression (incl. microarray and other genome-wide approaches)PharmacogenomicsMajor global burdens of diseaseGene and molecular therapyMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 12, 2025
Titin-related familial dilated cardiomyopathy: factors associated with disease onset.

Renee Johnson, Robert A Fletcher, Stacey Peters

|Aug 30, 2024
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Brendon L Neuen, Robert A Fletcher, Lauren Heath

|Apr 16, 2024
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.

Robert A Fletcher, William G Herrington, Rajiv Agarwal

|Apr 07, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.

Siddharth M Patel, Yu Mi Kang, KyungAh Im

|Nov 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.

Brendon L Neuen, Hiddo J L Heerspink, Priya Vart

|Oct 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

Abhinav Sharma, Pedro Marques, Brendon L Neuen

Pageof 2

Frequent Collaborators

7 joint publications

Brendon L Neuen

6 joint publications

Hiddo J L Heerspink

5 joint publications

Clare Arnott

5 joint publications

Vlado Perkovic